Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other indicationsAddition of remestemcel-L could expand Novartis res…
Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIsELARA results for Kymriah® in relapsed or refractory (r/r) follicular lymphoma, plus long-term JULI…
Novartis signed five virtual power purchase agreements (VPPAs), which are expected to collectively add 277 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve …
Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas emissions across its European operations, equivalent …
Novartis scientist Leila Haery likes to step away from the lab and wander in nature for perspective. While outdoors, the gene therapy expert contemplates the vastness of landscapes and their evolution over time. She’s inspired to ask new questions with…
Novartis maitained its strong position in the Dow Jones Sustainability World Index with a percentile score of 91 (vs. 87 in 2019). We are proud of our industry-leading performance in the areas of social and environmental reporting, human capital …
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2 Follows establishment of multi-disciplinary expert coalition and Novartis commitment to sharing data and findings with ophthalmology co…
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2Sustained LDL-C …
Translational immunologists from the Novartis Institutes for BioMedical …
The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint of reduced COVID-19 …